CA3248405A1 - Complement Factor Inhibitors and Their Uses - Google Patents

Complement Factor Inhibitors and Their Uses

Info

Publication number
CA3248405A1
CA3248405A1 CA3248405A CA3248405A CA3248405A1 CA 3248405 A1 CA3248405 A1 CA 3248405A1 CA 3248405 A CA3248405 A CA 3248405A CA 3248405 A CA3248405 A CA 3248405A CA 3248405 A1 CA3248405 A1 CA 3248405A1
Authority
CA
Canada
Prior art keywords
compound
mmol
disease
meoh
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3248405A
Other languages
English (en)
French (fr)
Inventor
Dean R. Artis
Colin P. Leslie
Luca B. Mileo
Claudia Beato
Federico Sorana
Bruno Di Guglielmo
Chiara Padroni
Federica Faroldi
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of CA3248405A1 publication Critical patent/CA3248405A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3248405A 2022-01-14 2023-01-13 Complement Factor Inhibitors and Their Uses Pending CA3248405A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263299712P 2022-01-14 2022-01-14
US63/299,712 2022-01-14
PCT/US2023/010783 WO2023137166A1 (en) 2022-01-14 2023-01-13 Inhibitors of complement factors and uses thereof

Publications (1)

Publication Number Publication Date
CA3248405A1 true CA3248405A1 (en) 2023-07-20

Family

ID=87279676

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3248405A Pending CA3248405A1 (en) 2022-01-14 2023-01-13 Complement Factor Inhibitors and Their Uses

Country Status (10)

Country Link
US (1) US12522619B2 (https=)
EP (1) EP4463462A4 (https=)
JP (1) JP2025502254A (https=)
KR (1) KR20240135818A (https=)
CN (1) CN118715231A (https=)
AU (1) AU2023207988A1 (https=)
CA (1) CA3248405A1 (https=)
IL (1) IL314164A (https=)
MX (1) MX2024008710A (https=)
WO (1) WO2023137166A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022020244A1 (en) 2020-07-20 2022-01-27 Annexon, Inc. Inhibitors of complement factors and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965583A (en) 1997-04-24 1999-10-12 Ortho-Mcneil Pharmaceutical, Inc. Substituted imidazoles useful in the treatment of inflammatory disease
EP1971664B1 (en) 2006-01-13 2015-09-09 LG Chem, Ltd. Emitting materials and organic light emitting device using the same
KR20100031723A (ko) * 2007-07-07 2010-03-24 이데미쓰 고산 가부시키가이샤 크리센 유도체 및 이를 이용한 유기 전계 발광 소자
KR101233377B1 (ko) * 2008-12-30 2013-02-18 제일모직주식회사 신규한 유기광전소자용 화합물 및 이를 포함하는 유기광전소자
WO2013049332A1 (en) * 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
DK3019240T3 (da) 2013-07-09 2024-06-03 Annexon Inc Anti-komplementfaktor C1Q antistoffer og anvendelser deraf
TWI532741B (zh) * 2013-09-04 2016-05-11 喜星素材股份有限公司 含吡唑之多環化合物及使用其之有機發光裝置
KR101635154B1 (ko) 2014-08-28 2016-06-30 (주)더블유에스 피리딜기가 결합된 트리아진 유도체 및 이를 포함한 유기 전계발광 소자
KR102233296B1 (ko) 2014-11-18 2021-03-29 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
AR103397A1 (es) 2015-01-13 2017-05-10 Syngenta Participations Ag Oxoborazoles microbicidas
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
KR101981245B1 (ko) * 2015-10-27 2019-05-22 주식회사 엘지화학 고리 화합물 및 이를 포함하는 유기 발광 소자
KR101806464B1 (ko) 2015-11-19 2017-12-07 (주)랩토 피리딜기가 결합된 피리미딘 유도체 및 이를 이용한 유기 전계 발광 소자
KR102496411B1 (ko) * 2016-01-06 2023-02-06 덕산네오룩스 주식회사 유기전기 소자용 화합물, 이를 이용한 유기전기소자 및 그 전자 장치
US10646488B2 (en) * 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2019240471A1 (ko) 2018-06-11 2019-12-19 주식회사 엘지화학 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자
WO2020032428A1 (ko) 2018-08-09 2020-02-13 덕산네오룩스 주식회사 유기전기 소자용 화합물을 포함하는 유기전기소자 및 그 전자 장치
CN109574917B (zh) 2018-12-03 2020-12-08 武汉尚赛光电科技有限公司 一种芴酮衍生物及其制备和应用
CN111087387B (zh) 2019-12-26 2022-04-29 厦门天马微电子有限公司 一种有机化合物、显示面板及显示装置
CN111423390A (zh) * 2020-03-30 2020-07-17 北京燕化集联光电技术有限公司 一种新型结构化合物及其应用
CN111662309B (zh) * 2020-07-10 2021-11-09 北京燕化集联光电技术有限公司 一种多杂环结构化合物及其应用
WO2022020244A1 (en) 2020-07-20 2022-01-27 Annexon, Inc. Inhibitors of complement factors and uses thereof
CN113045585A (zh) * 2021-03-16 2021-06-29 吉林奥来德光电材料股份有限公司 一种有机稠环化合物及其制备方法和应用
CN113831332B (zh) * 2021-10-29 2024-06-18 长春海谱润斯科技股份有限公司 一种含氮杂环衍生物及其在有机电致发光器件中的应用

Also Published As

Publication number Publication date
IL314164A (en) 2024-09-01
US12522619B2 (en) 2026-01-13
AU2023207988A1 (en) 2024-07-11
EP4463462A4 (en) 2025-06-25
EP4463462A1 (en) 2024-11-20
KR20240135818A (ko) 2024-09-12
MX2024008710A (es) 2024-09-27
CN118715231A (zh) 2024-09-27
WO2023137166A1 (en) 2023-07-20
JP2025502254A (ja) 2025-01-24
US20230265109A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
US12509474B2 (en) Inhibitors of complement factors and uses thereof
TW202323258A (zh) 用於治療血液病症之丙酮酸激酶活化劑
JP7675020B2 (ja) Ｂａｘ阻害剤およびその使用
WO2017027768A1 (en) Compositions and methods for treating tuberculosis
EP4232431B1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
US12522619B2 (en) Inhibitors of complement factors and uses thereof
EP3720438B1 (en) Heterocycle substituted pyridine derivative antifungal agents
CA3022195A1 (en) Compounds for modulating aquaporins
US20210101879A1 (en) AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE
EP4017844A1 (en) Compounds and use thereof for the treatment of infectious diseases and cancer
HK40116712A (zh) 补体因子抑制剂及其用途
WO2023250157A1 (en) Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
HK40096479A (zh) 补体因子的抑制剂和其用途
HK40101053B (en) Compounds and compositions for treating conditions associated with lpa receptor activity
HK40101053A (en) Compounds and compositions for treating conditions associated with lpa receptor activity

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240712

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20241218

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241218

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241218

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241219

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241227

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241227

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED

Effective date: 20250210

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250210